These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31515555)

  • 1. Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients.
    Kurk SA; Stellato RK; Peeters PHM; Dorresteijn B; Jourdan M; Oskam MJ; Punt CJA; Koopman M; May AM
    Am J Clin Nutr; 2019 Dec; 110(6):1395-1403. PubMed ID: 31515555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Creemers GM; Erdkamp FLG; de Jongh FE; Kint PAM; Poppema BJ; Radema SA; Simkens LHJ; Tanis BC; Tjin-A-Ton MLR; Van Der Velden A; Punt CJA; Koopman M; May AM
    Cancer Med; 2020 Feb; 9(3):1033-1043. PubMed ID: 31850687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients.
    Kurk SA; Peeters PHM; Dorresteijn B; de Jong PA; Jourdan M; Kuijf HJ; Punt CJA; Koopman M; May AM
    J Cachexia Sarcopenia Muscle; 2018 Oct; 9(5):909-919. PubMed ID: 30144305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
    Kurk S; Peeters P; Stellato R; Dorresteijn B; de Jong P; Jourdan M; Creemers GJ; Erdkamp F; de Jongh F; Kint P; Simkens L; Tanis B; Tjin-A-Ton M; Van Der Velden A; Punt C; Koopman M; May A
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):803-813. PubMed ID: 31094083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
    Goey KKH; Elias SG; van Tinteren H; Laclé MM; Willems SM; Offerhaus GJA; de Leng WWJ; Strengman E; Ten Tije AJ; Creemers GM; van der Velden A; de Jongh FE; Erdkamp FLG; Tanis BC; Punt CJA; Koopman M
    Ann Oncol; 2017 Sep; 28(9):2128-2134. PubMed ID: 28911067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
    Nakayama G; Ishigure K; Yokoyama H; Uehara K; Kojima H; Ishiyama A; Hayashi N; Takano N; Hattori N; Kobayashi D; Tanaka C; Hayashi M; Kanda M; Yamada S; Sugimoto H; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    BMC Cancer; 2017 Apr; 17(1):243. PubMed ID: 28376737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
    Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
    Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
    JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Bang YH; Kim JE; Lee JS; Kim SY; Kim KP; Kim TW; Hong YS
    Sci Rep; 2021 Mar; 11(1):7118. PubMed ID: 33782470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
    Munemoto Y; Kanda M; Ishibashi K; Hata T; Kobayashi M; Hasegawa J; Fukunaga M; Takagane A; Otsuji T; Miyake Y; Nagase M; Sakamoto J; Matsuoka M; Oba K; Mishima H
    BMC Cancer; 2015 Oct; 15():786. PubMed ID: 26497654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
    Suzuki N; Hazama S; Nagasaka T; Tanioka H; Iwamoto Y; Negoro Y; Yamauchi M; Kobayashi M; Okuda H; Fujishima N; Nishimura T; Yamanaka N; Toyota K; Mori Y; Nakagami Y; Shimokawa M; Nagano H; Okajima M
    Int J Clin Oncol; 2019 Oct; 24(10):1223-1230. PubMed ID: 31144145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Avallone A; Piccirillo MC; Nasti G; Rosati G; Carlomagno C; Di Gennaro E; Romano C; Tatangelo F; Granata V; Cassata A; Silvestro L; De Stefano A; Aloj L; Vicario V; Nappi A; Leone A; Bilancia D; Arenare L; Petrillo A; Lastoria S; Gallo C; Botti G; Delrio P; Izzo F; Perrone F; Budillon A
    JAMA Netw Open; 2021 Jul; 4(7):e2118475. PubMed ID: 34309665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
    Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
    Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.